Novartis AG ADR (NVS)vsXenon Pharmaceuticals Inc (XENE)

NVS

Novartis AG ADR

NYSE

$147.85

+3.44%

HEALTHCARE · Cap: $280.79B

XENE

Xenon Pharmaceuticals Inc

NASDAQ

$55.75

+2.24%

HEALTHCARE · Cap: $5.39B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 755553% more annual revenue ($56.67B vs $7.50M). NVS leads profitability with a 24.7% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).

NVS

Buy

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 5.5

Piotroski: 4/9Altman Z: 1.96

XENE

Avoid

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 7.3

Piotroski: 3/9Altman Z: 8.38

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-52.2%)

Margin of Safety

-52.2%

Fair Value

$109.78

Current Price

$147.85

$38.07 premium

UndervaluedFair: $109.78Overvalued

Intrinsic value data unavailable for XENE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.0/10

Market CapQuality

$280.79B10/10

Mega-cap, among the largest globally

Return on EquityProfitability

30.8%10/10

Every $100 of equity generates 31 in profit

Profit MarginProfitability

24.7%9/10

Keeps 25 of every $100 in revenue as profit

Operating MarginProfitability

27.8%8/10

Strong operational efficiency at 27.8%

Free Cash FlowQuality

$2.87B8/10

Generating 2.9B in free cash flow

XENE1 strengths · Avg: 10.0/10

Altman Z-ScoreHealth

8.3810/10

Safe zone — low bankruptcy risk

Areas to Watch

NVS4 concerns · Avg: 3.0/10

Revenue GrowthGrowth

2.2%4/10

2.2% revenue growth

Altman Z-ScoreHealth

1.964/10

Grey zone — moderate risk

PEG RatioValuation

2.532/10

Expensive relative to growth rate

EPS GrowthGrowth

-11.6%2/10

Earnings declined 11.6%

XENE4 concerns · Avg: 3.0/10

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Profit MarginProfitability

0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality

3/93/10

Weak financial health signals

Return on EquityProfitability

-51.8%2/10

ROE of -51.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.

Bull Case : XENE

The strongest argument for XENE centers on Altman Z-Score.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.

Bear Case : XENE

The primary concerns for XENE are EPS Growth, Profit Margin, Piotroski F-Score.

Key Dynamics to Monitor

XENE carries more volatility with a beta of 0.74 — expect wider price swings.

NVS is growing revenue faster at 2.2% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (51/100 vs 22/100), backed by strong 24.7% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders in Canada. The company is headquartered in Burnaby, Canada.

Compare with Other DRUG MANUFACTURERS - GENERAL Stocks

NVS vs LLY NVS vs JNJ NVS vs ABBV NVS vs AZN NVS vs MRK XENE vs LLY XENE vs JNJ XENE vs ABBV XENE vs AZN XENE vs MRK

Want to dig deeper into these stocks?

Full NVS Analysis →Full XENE Analysis →